Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IDEAYA Biosciences (IDYA) EBITDA Margin (2020 - 2025)

IDEAYA Biosciences (IDYA) has disclosed EBITDA Margin for 6 consecutive years, with 763.68% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 114112.0% to 763.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 51.32% through Dec 2025, up 386621.0% year-over-year, with the annual reading at 51.32% for FY2025, 386621.0% up from the prior year.
  • EBITDA Margin hit 763.68% in Q4 2025 for IDEAYA Biosciences, down from 57.63% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 57.63% in Q3 2025 to a low of 1904.8% in Q4 2024.
  • Historically, EBITDA Margin has averaged 464.06% across 5 years, with a median of 336.04% in 2023.
  • Biggest five-year swings in EBITDA Margin: plummeted -107250bps in 2024 and later surged 114112bps in 2025.
  • Year by year, EBITDA Margin stood at 637.2% in 2021, then rose by 10bps to 573.6% in 2022, then plummeted by -45bps to 832.3% in 2023, then crashed by -129bps to 1904.8% in 2024, then surged by 60bps to 763.68% in 2025.
  • Business Quant data shows EBITDA Margin for IDYA at 763.68% in Q4 2025, 57.63% in Q3 2025, and 1904.8% in Q4 2024.